Zobrazeno 1 - 10
of 141
pro vyhledávání: '"Afd Pharmacoepi & Clinical Pharmacology"'
Autor:
Narsai, K., Leufkens, H. G.M., Mantel-Teeuwisse, A. K., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Journal of Pharmaceutical Policy and Practice, Vol 14, Iss 1, Pp 1-10 (2021)
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice, 14(1), 1. BioMed Central
Journal of Pharmaceutical Policy and Practice
Journal of Pharmaceutical Policy and Practice, 14(1), 1. BioMed Central
Background Sub-Saharan Africa is going through an epidemiological transition, including an impressive increase in non-communicable diseases. The introduction of medicines has not kept pace with the needs in developing countries. The objectives of thi
Autor:
Cramer-Van der Welle, Christine M., Kastelijn, Elisabeth A., Plouvie, Bram C., Van Uden-Kraan, Cornelia F., Schramel, Franz M.N.H., Groen, Harry J.M., Van de Garde, Ewoudt M.W., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
JCO clinical cancer informatics, 5, 570-578. American Society of Clinical Oncology
JCO clinical cancer informatics, 5, 570. American Society of Clinical Oncology
JCO clinical cancer informatics, 5, 570. American Society of Clinical Oncology
PURPOSE To develop and evaluate a tool for patients with stage IV non–small-cell lung cancer and their thoracic oncologists (TOs) that provides insight into real-world effectiveness of systemic treatments to support informed clinical decision makin
Autor:
Révész, Dóra, Engelhardt, Ellen G, Tamminga, Johannes J, Schramel, Franz M N H, Onwuteaka-Philipsen, Bregje D, van de Garde, Ewoudt M W, Steyerberg, Ewout W, de Vet, Henrica C W, Coupé, Veerle M H, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Journal of Cancer Education, 35(2), 345. Springer Publishing Company
Journal of Cancer Education
Journal of Cancer Education, 35(2), 345-351. Springer Publishing Company
Révész, D R, Engelhardt, E G, Tamminga, J J, Schramel, F M N H, Onwuteaka-Philipsen, B D, van de Garde, E M W, Steyerberg, E W, de Vet, H C W & Coupé, V M H 2020, ' Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer ', Journal of Cancer Education, vol. 35, no. 2, pp. 345-351 . https://doi.org/10.1007/s13187-019-1471-8
Journal of Cancer Education
Journal of Cancer Education, 35(2), 345-351. Springer Publishing Company
Révész, D R, Engelhardt, E G, Tamminga, J J, Schramel, F M N H, Onwuteaka-Philipsen, B D, van de Garde, E M W, Steyerberg, E W, de Vet, H C W & Coupé, V M H 2020, ' Needs with Regard to Decision Support Systems for Treating Patients with Incurable Non-small Cell Lung Cancer ', Journal of Cancer Education, vol. 35, no. 2, pp. 345-351 . https://doi.org/10.1007/s13187-019-1471-8
Treatment decision-making for patients with incurable non-small cell lung cancer (NSCLC) is complex due to the rapidly increasing number of treatments and discovery of new biomarkers. Decision support systems (DSS) could assist thoracic oncologists (
Autor:
ten Ham, Renske M.T., Broering, Jeanette M., Cooperberg, Matthew, Carroll, Peter, Wilson, Leslie S., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Clinical Genitourinary Cancer, 18(1), E21. Elsevier
BACKGROUND: Localized prostate cancer (PCa) treatments provide high survival rates, with patients often surviving a decade or longer after treatment. Therefore, treatment options are progressively based on quality of life. The objective of this resea
Autor:
Li, Wenlong, Sparidans, Rolf W, Martins, Margarida L F, El-Lari, Mujtaba, Lebre, Maria C, van Tellingen, Olaf, Beijnen, Jos H, Schinkel, Alfred H, Afd Pharmacoepi & Clinical Pharmacology, Afd Pharmacology, Pharmacoepidemiology and Clinical Pharmacology, Pharmacology
Publikováno v:
Molecular Cancer Therapeutics, 20(6), 1173. American Association for Cancer Research Inc.
Selitrectinib (BAY2731954; LOXO-195) is a promising oral tropomyosin receptor kinase (TRK) inhibitor currently in phase I/II clinical trials for the treatment of histology-agnostic cancers positive for TRK fusions. With therapeutic resistance eventua
Autor:
Ebbelaar, Chiel F, Jansen, Anne M L, Bloem, Lourens T, Blokx, Willeke A M, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Virchows Archiv
Virchows Archiv, 479(4), 773. Springer Verlag
Virchows Archiv, 479(4), 773. Springer Verlag
Cutaneous intermediate melanocytic neoplasms with ambiguous histopathological features are diagnostically challenging. Ancillary cytogenetic techniques to detect genome-wide copy number variations (CNVs) might provide a valuable tool to allow accurat
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b9b0628358b038cf240bed86e209eff
https://dspace.library.uu.nl/handle/1874/413903
https://dspace.library.uu.nl/handle/1874/413903
Autor:
Dankers, Marloes, Nelissen-Vrancken, Marjorie H.J.M.G., Hart, Bertien H., Lambooij, Anke C., van Dijk, Liset, Mantel-Teeuwisse, Aukje K., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Pharmacology Research and Perspectives, 9(3):e00750. Wiley
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 9, Iss 3, Pp n/a-n/a (2021)
Pharmacology Research and Perspectives, 9(3), 1. Wiley-Blackwell Publishing Ltd
Pharmacology Research & Perspectives
Pharmacology Research & Perspectives, Vol 9, Iss 3, Pp n/a-n/a (2021)
Pharmacology Research and Perspectives, 9(3), 1. Wiley-Blackwell Publishing Ltd
To evaluate the clinical benefit of new medicines for type 2 diabetes mellitus (T2DM), the Dutch guideline committee T2DM in primary care established the importance of outcomes and minimal clinically important differences (MCIDs). The present study u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bf4aa4f0b973fe25158ac584a0cf7fa8
https://research.rug.nl/en/publications/143c9f77-4824-495e-bf8f-b208477a8914
https://research.rug.nl/en/publications/143c9f77-4824-495e-bf8f-b208477a8914
Autor:
Ismail, R. K., Schramel, F. M.N.H., van Dartel, M., Hilarius, D. L., de Boer, A., Wouters, M. W.J.M., Smit, H. J.M., Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Lung Cancer, 149, 68. Elsevier Ireland Ltd.
Lung Cancer, 149, 68-77. ELSEVIER IRELAND LTD
Lung Cancer, 149, 68-77. ELSEVIER IRELAND LTD
Objectives This study describes the initiation of the Dutch Lung Cancer Audit for Lung Oncology (DLCA-L) and reports the first results of three years of clinical auditing. Methods The initiation, dataset, and data quality of the DLCA-L are described.
Autor:
Alsamil, Ali M, Giezen, Thijs J, Egberts, Toine C, Leufkens, Hubert G, Gardarsdottir, Helga, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
Pharmaceuticals
Volume 14
Issue 3
Pharmaceuticals, Vol 14, Iss 189, p 189 (2021)
Pharmaceuticals (Basel, Switzerland), 14(3), 1. MDPI AG
Volume 14
Issue 3
Pharmaceuticals, Vol 14, Iss 189, p 189 (2021)
Pharmaceuticals (Basel, Switzerland), 14(3), 1. MDPI AG
Regulatory approval of biosimilars predominantly relies on biosimilarity assessments of quality attributes (QAs), particularly the potentially critical QAs (pCQAs) that may affect the clinical profile. However, a limited understanding exists concerni
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d9dfa195948044b2dc06552dfd653e5
https://dspace.library.uu.nl/handle/1874/411691
https://dspace.library.uu.nl/handle/1874/411691
Autor:
van Bussel, Mark T J, Beijnen, Jos H, Brandsma, Dieta, Afd Pharmacoepi & Clinical Pharmacology, Pharmacoepidemiology and Clinical Pharmacology
Publikováno v:
BMC Cancer, Vol 19, Iss 1, Pp 1-8 (2019)
BMC Cancer
BMC Cancer, 19(1). BioMed Central
BMC Cancer
BMC Cancer, 19(1). BioMed Central
Background Recently, two phase II trials showed intracranial activity of the immune checkpoint inhibitors nivolumab and ipilimumab in patients with melanoma brain metastases. However, it is generally assumed that large molecules like monoclonal antib